The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study

2014 ◽  
Vol 22 (9) ◽  
pp. 2409-2415 ◽  
Author(s):  
Michelle Nadler ◽  
Shabbir Alibhai ◽  
Pamela Catton ◽  
Charles Catton ◽  
Jennifer Jones
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Pilot Study ◽  
Bone Mineral ◽  
Androgen Deprivation ◽  
Mineral Density ◽  
Bone Mineral Density Testing ◽  
Fracture Assessment ◽  
The Impact

scholarly journals Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer

2020 ◽  
Vol 18 (10) ◽  
pp. 1374-1381
Author(s):  
Jason Hu ◽  
Armen G. Aprikian ◽  
Marie Vanhuyse ◽  
Alice Dragomir
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Fracture Risk ◽  
Androgen Deprivation Therapy ◽  
Bone Mineral ◽  
Androgen Deprivation ◽  
Primary Study ◽  
Mineral Density ◽  
Bone Mineral Density Testing ◽  
Bmd Testing

Background: Androgen deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer (PCa); however, it accelerates the loss of bone mineral density (BMD), which increases fracture risk. Guidelines recommend BMD testing when initiating ADT to assess baseline fracture risk properly. The objective of this study was to examine the proportion of BMD testing in men initiating ADT in Quebec and to identify factors associated with receipt of this testing. Methods: The study cohort consisted of men extracted from Quebec public healthcare insurance administrative databases who initiated continuous ADT from 2000 to 2015 for >12 months. The primary study outcome was receipt of BMD testing in the period from 6 months before through 12 months after ADT initiation. Multivariable generalized linear mixed regression modeling with a logit link was performed to identify variables associated with BMD testing. Results: We identified 22,033 patients, of whom 3,910 (17.8%) underwent BMD testing. Rates of BMD testing increased from 4.1% in 2000 to 23.4% in 2015. After multivariable analyses, prior history of osteoporosis (odds ratio [OR], 1.84; 95% CI, 1.32–2.57; P<.001), rheumatoid arthritis (OR, 1.64; 95% CI, 1.15–2.34; P=.006), use of bisphosphonates (OR, 1.47; 95% CI, 1.25–1.73; P<.001), and long-term corticosteroid use (OR, 1.63; 95% CI, 1.15–2.31; P=.006) were associated with higher odds of BMD testing. Patient age >80 years (OR, 0.67; 95% CI, 0.59–0.76; P<.001), metastases (OR, 0.79; 95% CI, 0.70–0.89; P<.001), higher Charlson comorbidity score (OR, 0.65; 95% CI, 0.51–0.81; P<.001), and rural residence (OR, 0.77; 95% CI, 0.68–0.87; P<.001) were associated with lower odds of BMD testing. Conclusions: In our study population, BMD testing rates in men initiating ADT were low, although they increased over the years especially in the years after the publication of recommendations for BMD testing in these patients. Potential gaps identified include being older, more comorbid, and rural areas. Overall, additional efforts emphasizing the importance of BMD testing in PCa guidelines may be needed.

scholarly journals Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer

2009 ◽  
Vol 103 (6) ◽  
pp. 753-757 ◽  
Author(s):  
Abbas H. Panju ◽  
Henriette Breunis ◽  
Angela M. Cheung ◽  
Marc Leach ◽  
Neil Fleshner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Androgen Deprivation Therapy ◽  
Bone Mineral ◽  
Androgen Deprivation ◽  
Mineral Density

Bone mineral density screening in patients with prostate cancer on androgen-deprivation therapy: Data from a single center

2014 ◽  
Vol 7 (5) ◽  
pp. 369-370
Author(s):  
Aileen Hariman ◽  
Dominick Bufalino ◽  
Brian Hess ◽  
Chike Obi ◽  
Ronald Price ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Androgen Deprivation Therapy ◽  
Bone Mineral ◽  
Androgen Deprivation ◽  
Single Center ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document